Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.

Interactions between ceacam and tim family members
Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between ceacam family members and tim family members.. .

Glycoengineered binding protein compositions
Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..

Compositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.

Synthetic n-acetyl-muramic acid derivatives and uses thereof
The present invention provides n-acetyl-muramic acid (nam) derivatives having formula i, wherein xa is selected from the group consisting of x1-x59, ya is selected from the group consisting of h, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and za is selected from the group consisting of oh, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing nam derivatives and methods for modulating nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to nam derivatives..

Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.. .

Sustained production of high affinity antigen specific antibody by high dose baff receptor-targeting mab-sirna conjugate
The present invention includes a composition and a method of modulating an immune response with a composition that comprises an anti-baff receptor antibody or binding fragment thereof that is bound or conjugated to an sirna, and shrna, or both, that targets a baff receptor mrna.. .

Consensus/ancestral immunogens
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of hiv primary isolates and/or to an immunogen that induces a t cell immune response. The invention also relates to a method of inducing anti-hiv antibodies, and/or to a method of inducing a t cell immune response, using such an immunogen.

Method and compositions for cellular immunotherapy
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific cd8+ t cells in the presence of tumor-specific, subset specific genetically modified cd4+ t cells, wherein the cd4+ t cells confer and/or augment a cd8+ t cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific cd8+ t cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described..

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Peptides and combination thereof for use in the immunotherapy against cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Immunogenic compositions and reagents for preparing

The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.. .

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time of original therapy and/or for later therapy.

Molecular adjuvant and vaccine

The invention relates to the fields of vaccines and vaccine adjuvants, and generally relates to polynucleotide adjuvants, polynucleotide vaccines and vaccine compositions. More specifically, the invention relates to said polynucleotides and vaccine compositions for use in inducing or enhancing a prophylactic or therapeutic immune response in a mammalian subject.

Anti-icos agonist antibodies and uses thereof

The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human inducible t cell costimulator (icos) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human icos activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided.

Controlled delivery of tlr agonists in structural polymeric devices

The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents..

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..

Pharmaceutical combination of everolimus with dactolisib

The present invention relates to a combination comprising (a) rad001, or a pharmaceutically acceptable salt thereof, and (b) bez235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.. .

Pd-1 antibodies and uses thereof

The present invention provides monoclonal antibodies that specifically bind to human pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Hepatitis c virus e1/e2 heterodimers and methods of producing same

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis c virus (hcv) e1 polypeptide and an hcv e2 polypeptide, where one or both of the e1 and e2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged e1/e2 heterodimer of the present disclosure.

Naphthyridines as inhibitors of hpk1

Naphthyridine compounds and their use as inhibitors of hpk1 are described. The compounds are useful in treating hpk1-dependent disorders and enhancing an immune response.

Isoquinolines as inhibitors of hpk1

Isoquinoline compounds and their use as inhibitors of hpk1 (hematopoietic kinase 1) are described. The compounds are useful in treating hpk1-dependent disorders and enhancing an immune response.

Methods and compositions for liposomal formulation of antigens and uses thereof

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“dmpc”); either dimyristoylphosphatidylglycerol (“dmpg”) or dimyristoyltrimethylammonium propane (“dmtap”) or both dmpc and dmtap; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s)..

Compounds and therapeutic uses thereof

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.. .

Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists

Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise pd-1 axis antagonists and hpk1 antagonists.

Aluminum based adjuvants for tolerogenic vaccination

The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier.

Expression vector delivery system and use thereof for inducing an immune response

Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.

Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy

The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant listeria strain expressing a construct comprising at least one human papillomavirus antigen.. .

Nanoparticle based tumor endothelial targeting vaccine

Disclosed are methods, compositions of matter, and therapeutic protocols for treatment of cancer by selectively inducing immune responses against blood vessels feeding neoplastic tissue. In one embodiment, placental endothelial cells are stimulated with phorbol myristate acetate (pma) to induce release of nanoparticles that possess ability to: a) be taken up by antigen presenting; b) presented through direct and indirect presentation to cd4 and cd8 t cells, respectively; and c) utilized to stimulate cytoxic t cellular and humoral responses to selectively inhibit angiogenesis of tumors..

Retinoid compositions and methods of increasing immune cell-mediated killing of idh mutant cancer cells

Provided herein are methods of treating an idh mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (atra). In some embodiments, the methods increase an nk-cell-mediated immune response and/or a t cell-mediated immune response to the cancer.

Deimmunized therapeutic compositions and methods

This disclosure provides a bispecific ligand directed toxin (blt) that includes a diphtheria toxin (dt) molecule that has been mutated to create a dt molecule that induces less of an immune response than native diphtheria toxin. The deimmunized dt molecule is fused with targeting ligands to create a fusion protein that can selectively deliver the deimmunized dt to target cells to kill the target cells..
Regents Of The University Of Minnesota

Human immune therapies using a cd27 agonist in combination with another immune agonist to treat cancer

Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton

Combination therapy for treatment of disease

The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases..
Oncomed Pharmaceuticals, Inc.

Multi-epitopic construct

The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis.
Thrombosis Research Institute

Methods of modulating immune responses using bcma polypeptide

A novel receptor in the tnf family is provided: baff-r. Chimeric molecules and antibodies to baff-r and methods of use thereof are also provided..
Topotarget Switzerland Sa

Immune cell compositions and methods of use

Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (car), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the car binds to a cancer antigen. Also disclosed herein are t cells that recognize and are sensitized to a cancer antigen, which t cells recombinantly express a dominant negative form of an inhibitor of a t cell-mediated immune response.
Memorial Sloan Kettering Cancer Center

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Biomaterials for combined radiotherapy and immunotherapy of cancer

Compositions and methods for the radiological and immunotherapeutic treatment of cancer are provided. Metallic nanoparticles conjugated with an immunoadjuvant are dispersed within a biodegradable polymer matrix that can be implanted in a patient and released gradually.
The Brigham And Women's Hospital, Inc.

Herpes simplex virus type-1(hsv-1) vaccine strain vc2 generating an anti-ehv-1 immune response

The disclosure encompasses recombinant nucleic acids comprising a nucleotide sequence encoding a live-attenuated chimeric herpes simplex virus type-1 (hsv-1) vc2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein d (gd) of equine herpesvirus-1 (ehv-1) or a fragment thereof.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechan

Design and characterization of influenza vaccines

Provided herein are optimized, recombinant influenza ha polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized ha polypeptides as well as methods of making and using the optimized ha polypeptides..
Oregon Health & Science University

Live attenuated heterologous vaccine for leptospira

The present invention provides compositions or vaccines that contain a recombinant or an attenuated leptospira interrogans that elicit an immune response in animals against leptospira infection, including compositions comprising said recombinant or attenuated l. Interrogans, methods of vaccination against leptospira, and kits for use with such methods and compositions..
Institut Pasteur

Immunogenic composition against campylobacter jejuni

The inventive subject matter relates to an immunogenic composition against campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-c.

Manufacturing an immunotherapeutic formulation comprising a recombinant listeria strain

The present invention discloses a process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant listeria comprising a human papilloma virus (hpv) antigen fused to a listeriolysin o (llo) protein fragment. The invention further discloses methods of using treating, protecting against, and inducing an immune response against cervical cancer comprising administration of the recombinant listeria strain.
The Trustees Of The University Of Pennsylvania

Rna preparations comprising purified modified rna for reprogramming cells

The present invention provides compositions and methods for reprogramming somatic cells using purified rna preparations comprising single-strand mrna encoding an ips cell induction factor. The purified rna preparations are preferably substantially free of rna contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mrna in the somatic cells, and/or iii) active rna sensors in the somatic cells.
The Trustees Of The University Of Pennsylvania

Methods for controlling t cell proliferation

The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of t cells, for example, therapeutic t cells. The methods further relate to compositions and methods for inducing an immune response in a subject..
Bellicum Pharmaceuticals, Inc.

Combined tissue resonance suppression therapy and autologous polyvalent biological vaccine

A method for strengthening the immune response of a weakened immune system, wherein the method includes providing a doses of tissue resonance suppression therapy to a patient and injecting an autologous polyvalent biological vaccine to the patient, wherein the autologous polyvalent biological vaccine was produced from the patient venous blood, a system for performing tissue resonance suppression therapy, a system and a process for the production of the autologous polyvalent biological vaccine for treating cancer, and an autologous polyvalent biological vaccine for personalized and precision medicinal, for treatment of individual cancerous patients, wherein producing a new dose of autologous polyvalent biological vaccine is done from a patient venous blood that was taken after time interval from the time in which a previous venous blood was taken, wherein the vaccine is adapted for treating the individual cancerous patients at a specific stage of his disease, in accordance with embodiments of the present invention.. .

Particles comprising a shell with rna

The present invention relates to rna decorated particles such as rna decorated lipid particles, preferably to rna decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising rna decorated particles such as rna decorated lipid particles, preferably rna decorated liposomes.
Tron - Transtionale Onkologie An Der Universitatsmedizin Der Johannes Gutenb

Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis

Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, f1 and v from yersinia pestis and pa antigen from bacillus anthracia fused in-frame and retaining structural and functional integrity of all three antigens.
The Catholic University Of America

Ompa and asp14 in vaccine compositions and as diagnostic targets

Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof

Disclosed herein are immunogenic glycopeptide compounds for inducing immune responses to prevent and/or treat cancer. Other aspects of the present disclosure are pharmaceutical compositions comprising the immunogenic glycopeptide compounds, and methods using the compounds for preventing and/or treating a cancer in a subject..
Dcb-usa, Llc

(en) potentiated t-cell modulator able to modulate immune response, extracting, testing and counting a dialysable leucocyte extract from shark spleen to produce same, and therapeutic use thereof

The present invention relates to a potentiated t-cell modulator (tcm), with a potency of 1012 leucocytes/mm3, obtained from a dialysed extract of leucocytes from the spleen of selachimorpha or sharks that contains peptides equal to or less than 10,000 da, in powder form. The invention also relates to the use of the tcm to produce a medicine for treating diseases related to the regulation of immune response such as cancer or viral infections..

Immunotherapy of aberrant ocular angiogenesis by placental vaccination

Disclosed are materials, methods, and protocols for inducing a therapeutic response in ocular conditions, such as diabetic retinopathy and wet macular degeneration, by immunizing with placental endothelial cells. In one embodiment, the invention teaches the administration of placental endothelial cells or products thereof, in an immunogenic context to induce antibody and/or cellular immune responses towards ocular neovascularization.
Batu Biologics, Inc.

Composition for treating inflammatory disease induced by hyperimmune response

Provided is a cell therapeutic agent for treating an inflammatory disease induced by a hyperimmune response, more specifically, a composition for treating an inflammatory disease induced by a hyperimmune response, which comprises (i) a chondrocyte or a cell capable of differentiating into a chondrocyte; and (ii) a chondrocyte into which a gene encoding tgf-β is introduced or a cell capable of differentiating into a chondrocyte into which a gene encoding tgf-β is introduced.. .
Kolon Life Science, Inc.

Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and rna. Further, the present invention relates to a pharmaceutical composition comprising such particles.
Tron-translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-univers

Compounds for inducing anti-tumor immunity and methods thereof

Described herein is a previously unknown function of xbp1 in controlling anti-tumor immunity. It is shown that inhibiting xbp1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses..

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Improved methods and compounds for eliminating immune responses to therapeutic agents

The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an mhc class ii t cell epitope or a cd1 d-restricted nkt cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [cst]-x(2)-c [seq id no:7] or c-x(2)-[cst] [seq id no:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein..

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Single-cycle virus for the development of canine influenza vaccines

The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (civ) and civ-related pathology. The present invention is based in part upon the discovery that one or more mutations in segment 4 of the viral genome produces a single cycle infectious civ (sciciv).

Process for preparing an attenuated tetravalent dengue vaccine

The present invention refers to a process for preparing an attenuated tetravalent dengue vaccine and its product. The present invention also refers to a process for preparing a tetravalent dengue vaccine for administration to a subject, to a method for inducing an immune response to virus dengue serotype 1, 2, 3 and 4 in a patient and to a tetravalent dengue vaccine kit..

Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna, preferably a mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (nsclc), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto.

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Long chain inulin for stimulating an immune response

The invention relates to a long chain inulin for influencing the immune response against a pathogen. The invention also relates to a combination comprising a long chain inulin and a vaccine for influencing the immune response against a pathogen, wherein the long chain inulin is orally administrated..

Methods and compositions for treating cancers using antisense

The present disclosure relates to compositions and methods for treating cancers using antisense (as) nucleic acids directed against insulin-like growth factor 1 receptor (igf-1r). The as may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine.

Systems for producing cellular immunotherapeutics and methods of use thereof

Devices, systems, and methods can be used for the automated production of dendritic cells (dc) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own dc for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease..
Northeastern University

Compositions and methods for modulating immune responses

The present invention provides a newly identified b7 receptor, zb7r1 that functions as lymphocyte inhibitory receptor, which is a pd-1-like molecule and is expressed on t cells. The present invention also provides the discovery of zb7r1's ability to bind to cd155.
Zymogenetics, Inc.

Mesothelin-targeted chimeric antigen receptors and uses thereof

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (cars) that specifically target human mesothelin, and immunoresponsive cells comprising such cars.
The U.s.a. As Represented By The Secretary, Department Of Health And Human Services

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response

The use of compositions comprising a papaya mosaic virus (papmv) moiety for stimulation of the innate immune response is provided. The papmv moiety may be papaya mosaic virus or papmv virus-like particles (vlps).
Folia Biotech Inc.

Compositions and methods for inducing and enhancing an immune response

The present invention relates to compositions and methods for modulating immune responses using at least one cycli di-nucleotide synthetase enzyme gene. Such compositions may be combined with a number of other therapeutics which target modulating immune responses, as well as, treatments that include immune events..
Board Of Trustees Of Michigan State University

Compositions against cat allergy

The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat.
UniversitÄt ZÜrich

Methods of treating and preventing influenza infections

The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection..
Longhorn Vaccines And Diagnostics, Llc

Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases

The present disclosure relates to an immunostimulatory combination comprising a therapeutic vaccine and a pd-1-related blockade for treating human papillomavirus (hpv) associated diseases. The combination generates a more potent response against hpv-associate diseases by stimulating the immune response of immune cells..
Papivax Biotech Inc.

Bacillus based delivery system and methods of use

Herein a bacillus exosporium antigen delivery (bead) system that provides a means to introduce recombinant proteins or small molecules into the exosporium of members of the b. Cereus family of bacteria, i.e.
The Curators Of The University Of Missouri

Novel methods for inducing an immune response

The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide rv1196 related antigen and at least one administration of an adenovirus encoding a rv1196 related antigen or (ii) at least one administration of a polypeptide rv0125 related antigen and at least one administration of an adenovirus encoding a rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided..
Glaxosmithkline Biologicals, Sa

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Tumor infiltrating lymphocytes for treatment of cancer

Tumor infiltrating lymphocytes (tils) are white blood cells that are actively recruited to the tumor site to mount an immune response against tumor growth and metastasis. The disclosure provides methods for treating cancer that comprise steps of isolating cd8+ t cells from a sample derived from a subject, expanding the cd8+ t cells in the presence of interleukin-10, and administering the expanded cd8+ t cells to the subject.
Duke University

Compositions and methods for restoring the immune system

A pharmaceutical composition for shifting a th2 immune response to a th1 response by natural killer t cells (nkt cells) including a therapeutically effective amount of a glycolipid of one or more of formulas ii-v or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier is provided.. .
Orpheus Therapeutics, Inc.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Lectin compositions and methods for modulating an immune response to an antigen

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide.
Opsanitx Llc

Polynucleotides for treating oncogenic viral polypeptide positive tumors

This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use.
Sanford Health

Pre-fusion rsv f antigens

The invention relates to pre-fusion rsv f protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion rsv f..
Glaxosmithkline Biologicals, Sa

Guanidine substituted imidazo[4,5-c] ring compounds

Imidazo[4,5-c] ring compounds, (particularly imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a guanidine substituent at the 1-position, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed..
3m Innovative Properties Company

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)i;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

The present invention provides pharmaceutical compositions comprising a vegf antagonist and an anti-ctla-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial..
Regeneron Pharmaceuticals, Inc.

Methods of using a vaccine composition containing synthetic adjuvant

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
Infectious Disease Research Institute

Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immume checkpoint blocking agents for solid tumors

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia ankara (mva) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor..
Memorial Sloan-kettering Cancer Center

Dna vaccines encoding heat shock proteins

A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

Antibody to cytolethal distending toxin of campylobacter jejuni

Methods for preventing ibs, reducing the likelihood of developing ibs and/or treating ibs by administering cot inhibitors and/or cot neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent ibs or to reduce the likelihood of developing or having ibs are also provided.
Cedars-sinai Medical Center

Compositions and methods for modulating an immune response

The invention provides methods of modulating follicular regulatory t (tfr) cell-mediated immune responses, follicular helper t (tfh) cell-mediated immune responses or both, and the use of those methods in the treatment of diseases or conditions mediated by tfr or tfh cells. The invention also provides novel methods for identifying tfr and tfh cells in a population of cells.
President And Fellows Of Harvard College

Humanized anti-dkk2 antibody and uses thereof

The present invention relates to the discovery that inhibition of dickkopf2 (dkk2) increases cd8+ cytotoxic t lymphocyte (ctl) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-dkk2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a t cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject.
Yale University

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats

The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as hiv, siv, or fiv. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses.
University Of Florida Research Foundation, Inc.

Fusion molecule based on taa variant

This invention provides novel carbonic anhydrase (caix) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. Vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a caix antigenic marker.
The Regents Of The University Of California

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

The success of anti-tumor immune responses requires effector t cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (dpp4, also known as cd26) limits lymphocyte migration to sites of inflammation and tumors.
Institut National De La Sante Et De La Recherche Medicale (inserm)

Composition containing extracellular polysaccharide produced by ceriporia lacerata as active ingredient for immunoregulation

The present invention relates to an extracellular polysaccharide produced by ceriporia lacerata, a culture medium of ceriporia lacerata hyphae including the extracellular polysaccharide, a composition for immunoregulation containing, as an active ingredient, dried powder of the hyphae culture medium or an extract of the hyphae culture medium, a pharmaceutical composition for preventing or treating an immune disease, and a health food for immunoregulation. The composition of the present invention has an excellent effect on immune enhancement and overactive immune response inhibition..
Fugenbio Co., Ltd.

Using phage epitopes to profile the immune response

The present disclosure provides compositions and methods for using one or more polypeptide probes to profile an immune response. The polypeptide probe can be used to detect one or more antibodies from a sample.
Exact Sciences Development Company, Llc

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof

Polypeptides, agents, and molecules that bind lymphotoxin-beta receptor (ltβr) and/or tumor-associated antigens are disclosed. The polypeptides, agents, or molecules may include, without limitation, fusion or single-chain lymphotoxin-αββ polypeptides and homodimer and heterodimer molecules comprising the lymphotoxin-αββ polypeptides.
Oncomed Pharmaceuticals, Inc.

Epitope focusing by variable effective antigen surface concentration

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient.
Distributed Bio, Inc.

Depdc1-derived peptide and vaccine containing same

The present invention provides depdc1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Compositions and methods for immunomodulation

The present invention relates to modulation of the tumor microenvironment to increase cancer specific immune responses. Conjugates, nanoparticles and formulations of the present invention relieve the inhibitory effect induced by tumor cells, and enhance antitumor immunity.
Tarveda Therapeutics, Inc.

Compositions and methods for immuno-oncology therapies

The present invention relates to cancer immunotherapy. Conjugates and nanoparticles comprising active agents that can elicit a cancer specific immune response are provided.
Tarveda Therapeutics, Inc.

Monovalent anti-cd3 adjuvants

This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research

Vaccine composition containing synthetic adjuvant

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
Infectious Disease Research Institute

Anti-malaria compositions and methods

Described herein are multilayer films that include modified polypeptide epitopes from plasmodium falciparum, specifically a modified t* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host.
Artificial Cell Technologies, Inc.

Immunogenic compositions, antigen screening methods, and methods of generating immune responses

An immunogenic composition is provided herein. The immunogenic compositions are used to identify and select immunogenic antigens that elicit immune responses in a subject and may be subsequently used in multi-antigen vaccine compositions against one or more diseases or conditions.
University Of Washington

Biological systems for production of highest quality proteins

Vaccines and therapeutic proteins, including polyclonal and monoclonal antibodies, must be maximally pure and stable in their most active native form. This is a requirement for their maximal efficacy, specificity and stability as well as for precluding immune responses against erroneous or damaged moieties.
Mediterranean Institute For Life Sciences

Compositions and methods for regulating nk cell activity

The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects.
Innate Pharma

Method for enzymatic treatment of tissue products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix.
Lifecell Corporation

Vista modulators for diagnosis and treatment of cancer

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of vista, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as pd-1.
The Trustees Of Dartmouth College

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Pyrimidines and uses thereof

Wherein r1-r5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.. .

Method for eliciting an immune response to an immunogen

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for immunogen.. .
Agency For Science, Technology And Research

Immunogenic protein pas n 1 from bahia grass pollen

The present invention relates generally to novel recombinant polypeptides of bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same.
The University Of Queensland

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a factor h binding protein (fhbp) and a neisseria meningitidis non-serogroup b capsular polysaccharide. The invention further relates to uses of a composition that includes fhbp, such as, for example, uses to elicit an immune response against n.
Pfizer Inc.

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
Oncomed Pharmaceuticals, Inc.

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
Cellectis

Methods for enhancing an immune response

Methods and compositions for enhancing an immune response in a subject (e.g., an immunocompromised subject or a subject with systemic lupus erythematosus (sle)) are described. In particular, methods of administering to the subject an effective amount of an anti-signaling lymphocytic activation molecule family member 7 (slamf7)-antibody or antigen binding fragment thereof are described..
Beth Israel Deaconess Medical Center

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Composition for preventing mycoplasma spp. infection

The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against mycoplasma spp. The present invention also provides a subunit vaccine made therefrom.
Agricultural Technology Research Institute

Immunogenic wt-1 peptides and methods of use thereof

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt1-expressing cancer, comprising heteroclitic peptides derived from the wt-1 protein.. .
Memorial Sloan Kettering Cancer Center

Anti-tumour immune responses to modified self-epitopes

The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mab) therapy.
Scancell Limited

Methods of using interleukin-10 for treating diseases and disorders

Methods of modulating immune responses in subjects having oncology- and immune-related diseases, disorders and conditions by the administration of an il-10 agent, including pegylated il-10.. .
Armo Biosciences, Inc.

Porcine immune modulation model

A method of modulating an immune response. The method includes administering a treatment comprising delta 5-androsten-3b, 17b-diol, delta 5-androsten-3b, 7b, 17b-triol, or both..
Government Of The United States As Represented By The Secretary Of The Air Force

Human herpesvirus immunotherapy

An isolated protein comprises respective amino acid sequences of each of a plurality of ctl epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said ctl epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, transporter associated with antigen processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic t lymphocytes (ctl) in vitro and eliciting a ctl immune response in vivo upon administration to an animal as an exogenous protein.
The Council Of The Queensland Institute Of Medical Research

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection.
Seqirus Uk Limited

Immunogenic compositions containing bacterial outer membrane vesicles

This invention relates to outer membrane vesicles (omvs) from gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane.
Universita' Degli Studi Di Trento

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of gvydgeehsv (seq id no: 303), in which the peptide is in a complex with an mhc molecule.. .
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compositions and methods for modulating and/or stimulating immune responses in human and/or animal

There is provided a composition including parietal polysaccharides from at least one candida species and parietal polysaccharides from at least one different yeast species. The composition can be used in modulating and/or stimulating immune responses in animal or human..
Danstar Ferment Ag

Peptide combinations and uses thereof for treating grass allergy

The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. The allergens phl p 1, phl p 2, phl p 3, phl p 4 and/or phl p 5, or a peptide variant thereof.
La Jolla Institute For Allergy And Immunology

Use of oncolytic herpes simplex virus, alone or in combination with immune check-point inhibitor, in the treatment of cancer

An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor.. .
Virttu Biologics Limited

Treatment to promote wound healing

The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing.
Rutgers, The State University Of New Jersey

Methods and compositions for enhancing immune response to vaccination

Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition..
Emv Enhance (hk) Limited

Microdroplet based bioassay platform

Platform technology involving aqueous microdroplet reaction vessels created, arrayed, and characterized by imaging microscopy in a microfluidic device are applied to a wide variety of bioassays involving the detection and phenotypic characterization of single cells. The bioassays include the rapid and automated detection of microbial pathogens and their antibiotic sensitivity from patient samples as well as the characterization of immune responses using a patient's own cells, including the killing of tumor cells..
Northeastern University

Methods and compositions for treating cancers using antisense

The present disclosure relates to compositions and methods for treating cancers using antisense (as) nucleic acids directed against insulin-like growth factor 1 receptor (igf-1r). The as may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine.
Thomas Jefferson University

Compounds for inducing anti-tumor immunity and methods thereof

Described herein is a previously unknown function of xbp1 in controlling anti-tumor immunity. It is shown that inhibiting xbp1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses..
Cornell University

Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptors and adaptors thereof

Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and cd40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing cd40 activity without prostaglandin e2.
Baylor College Of Medicine

Methods and compositions for inhibiting akt3

Compounds and compositions for selectively inhibiting akt3 are provided. Methods of using the compounds are also provided.
Augusta University Research Institute, Inc.

Lipidated immune response modifier compound compositions, formulations, and methods

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c] quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company

Dickkopf2 (dkk2) inhibition suppresses tumor formation

The present invention relates to the discovery that inhibition of dickkopf2 (dkk2) increases cd8+ cytotoxic t lymphocyte (ctl) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of dkk2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a t cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject.
Yale University

Euglena derived composition having biomass and immune response inducing components

A composition includes a euglena whole cell biomass and cellular components, including beta-1,3-glucan as at least about 90 percent linear, unbranched beta-1,3-glucan polysaccharide polymers having an average molecular weight of 1.2 to 580 kilodaltons (kda) and beta-glucan polymer chains having a polymer length of about 7.0 to 3,400 glucose monomers. Residual media remains from a heterotrophic fermentation process that produced the euglena biomass.
Algaeon, Inc.

Method and compositions for cellular immunotherapy

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain.
Seattle Children's Hospital, Dba Seattle Children's Research Institute

Modular particulars for immunotherapy

Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle.
Yale University

Protease cleavage site peptides as an hiv vaccine

Instead of generating immune responses to several hiv proteins and risk over activating more cd4+ t cells (easy targets for hiv-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific cd8+ t cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more cd4+ t cells and provide more targets for hiv-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites..
Her Majesty The Queen In Right Of Canada As Repres Ented By The Minister Of Health

Propionibacterium fruedenreichii as a probiotic for infants

The invention pertains to the benefits of propionibacterium freudenreichii supplementation in infant foods, for example, preterm infant foods such as human donor milk or infant milk formula. Accordingly, the invention provides a method of administering an infant food comprising a pharmaceutically effective amount of p.
University Of Florida Research Foundation, Inc.

Strings of epitopes useful in diagnosing and eliciting immune responses to sexually transmitted infections

The invention provides methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (soe) specific for detection of causative microorganisms. The antigenic epitopes may be single epitope sequences, a plurality of epitope sequences joined by repeats of glycine (-gg-) and/or lysine (-kk-) to form a series of epitopes (soe), or nucleotide sequences encoding one or more soes and host cells harboring said soe nucleotide sequences.
Washington State University

Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined rna virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said rna virus or against both measles virus and against said rna virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition..
Centre National De La Recherche Scientifique

Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections

The present invention is drawn to conjugates and vaccine compositions comprising a pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more klebsiella surface polysaccharide antigens, such as klebsiella pneumoniae o polysaccharide from serovars o1, o2a, o2a,c, o3, o4, o5, o7, o8 and o12. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions..

Novel promiscuous hpv16-derived t helper epitopes for immunotherapy

The present invention relates to novel amino acid sequences of peptides derived from hpv 16 that are able to bind to mhc complexes of class ii, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and t-cells, based on said epitopes..
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts

Patterned dosing of immunosuppressants coupled to synthetic nanocarriers

Provided herein are methods and related compositions for administering viral vectors and synthetic nanocarriers comprising an immunosuppressant. In some embodiments, the methods and compositions provided herein achieve improved transgene expression and/or immune response reduction, such as downregulated igm and/or igg immune responses..
Selecta Biosciences, Inc.

Novel mucosal vaccination approach for herpes simplex virus type-2

Methods and kits for immunizing animals (e.g. Mammals) against viral antigens, including herpes-simplex virus type 2 are provided.
Biomedical Research Models, Inc.

Concomitant dengue and yellow fever vaccination

The present invention relates to a yellow fever (yf) vaccine for use in a method for inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said yellow fever vaccine to a human subject together with a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4. This invention also pertains to a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4 for use in a method of inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said tetravalent dengue vaccine to a human subject together with a yellow fever (yf) vaccine..
Sanofi Pasteur

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Induction of lamina propria regulatory t cells

Described herein are methods and compositions for the induction of the production of regulatory t cells and for the treatment and/or prevention of diseases associated with pathological immune responses, such as inflammatory bowel diseases.. .
President And Fellows Of Harvard College

3m Innovative Properties Company

. .

Methods and compositions for combination immunotherapy

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Compositions comprising nucleic acids and methods of using the same

The disclosure relates to compositions comprising and methods for chemical modification of single guide rna (sgrna), tracrrna and/or crrna used individually or in combination with one another or cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgrna.
Massachusetts Institute Of Technology

Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual.
Northwest Biotherapeutics, Inc.

Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom

Wherein a is ch or n, p is in a range from 1 to 50, r″ is a bond or -alkylene-o—, r′ is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and e is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.

Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous dna sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer.
Trieza Therapeutics, Inc.

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (odn) sequence conjugated to a short-activating rna (sarna) or an antisense oligonucleotide sequence (aso), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating cebpa, and method of reducing activity of stat transcription factor, by one of the disclosed compounds or compositions.. .
City Of Hope

Peptide sequences and compositions

The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a t cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.. .
Peptcell Limited

Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus ankara-based (mva-based) vaccine against fmdv infection and to related products, methods and uses.
Bavarian Nordic A/s

Chimeric proteins

The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalising an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins..
The Australian National University

Allogenic tumor cell vaccine

The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed igg1, cd40l, tnf-alpha, as well as membrane and soluble forms of gm-csf, and flt-3l peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate.
Alloplex Biotherapeutics

Immune checkpoint chimeric antigen receptors therapy

In some aspects, the embodiments relate to compositions and methods related to chimeric transmembrane proteins. The chimeric transmembrane proteins may comprise the extracellular domain of an inhibitory receptor, and an intracellular signaling domain that can activate an immune response..
The Johns Hopkins University

Milk-derived microvesicle compositions and related methods

A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum.
University Of Louisville Research Foundation, Inc.

Allogeneic autophagosome-enriched composition for the treatment of disease

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
Providence Health & Sevices-oregon

Methods and compositions for treating celiac disease

The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor cm3, alpha amylase inhibitor 0.19 (0.19), cm1, cm2, cma, cmd, cm 16, cmb, cmx1/cmx3, cmx2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to cm3, 0.19, cm1, cm2, cma, cmd, cm16, cmb, cmx1/cmx3, cmx2, and/or 0.53, food products containing reduced levels of cm3, 0.19, cm1, cm2, cma, cmd, cm1 6, cmb, cmx1/cmx3, cmx2, and/or 0.53 protein, the use of oral tlr4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying cm3, 0.19, cm1, cm2, cma, cmd, cm16, cmb, cmx1/cmx3, cmx2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to cm3, 0.19, cm1, cm2, cma, cmd, cm 16, cmb, cmx1/cmx3, cmx2, and/or 0.53 triggered innate immune responses..
Beth Israel Deaconess Medical Center, Inc.

Ceacam1 mediated protective immunity

The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

Adjuvanted formulations of booster vaccines

The invention improves tdap vaccines by including a tlr agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response..
Glaxosmithkline Biologicals Sa

Immunomodulator compounds and methods of use

Compositions and methods for inducing pd-l1 internalization are disclosed. The methods include reducing the amount of cell surface pd-l1 by contacting a cell expressing pd-l1 with a compound that binds to cell surface pd-l1 and induces pd-l1 internalization.
Incyte Corporation

Compositions for modulating an xbp1 pathway in a keratinocyte and methods of use

Provided herein are compositions and methods for increasing an immune response in a subject, immunizing a subject and/or treating a disease in a subject that relate to keratinocytes. It is a surprising finding of the present invention that modulation of an xbp1 pathway creates a keratinocyte that is itself an immune modulator, or adjuvant.
University Of Pittsburgh-of The Commonwealth System Of Higher Education

Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins

The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins.
Texas Biomedical Research Institute

Synthetic antigen constructs against campylobacter jejuni

The invention relates to immunogenic synthetic constructs capable of inducing an immune response against campylobacter jejuni (c. Jejuni) in a subject comprising one or more monosaccharides comprising one or more meopn moieties.
United States Of America As Represented By The Secretary Of The Navy

Immunogenic compositions against tuberculosis

Methods of preparing mutants of mycobacterium tuberculosis with one or more disrupted genes are presented, where the disrupted genes include ctpv, rv0990c, rv0971c, and/or rv0348. Compositions containing mutants with attenuated virulence and pathogenesis, which are capable of stimulation of an immune response against tuberculosis, are described.
Wisconsin Alumni Research Foundation

Compositions and methods for modulating pro-inflammatory immune response

Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
Icahn School Of Medicine At Mount Sinai

. .

Diagnostic target

A method for the diagnosis of type 1 diabetes, or a predisposition towards type 1 diabetes, or to monitor the efficacy of a therapy to prevent or treat type 1 diabetes, said method comprising contacting a sample from a subject with a reagent selected from tetraspanin-7 or a fragment, or a modified form thereof, and detecting an interaction indicative of the presence of an autoimmune response to tetraspanin-7. Tetraspanin-7 is now understood to be the protein recognised by glima 38 specific antibodies.
The University Of Lincoln

Allogeneic autophagosome-enriched composition for the treatment of disease

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
Providence Health & Sevices-oregon

Development of dengue virus vaccine components

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-utr) comprising a Δ30 mutation that removes the tl-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-utr that removes sequence in the 5′ direction as far as the 5′ boundary of the tl-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-utr of a dengue virus of a first serotype with the 3′-utr of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-utr; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.. .
The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt

Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses

The finding that phosphatidylserine (ptdser) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (plscr1) activity prevents ptdser externalization and enables prolonged protection of vector-transduced cells from phagocytosis.
Salk Institute For Biological Studies

Dendritic cell generator

Devices, systems, and methods can be used for the automated production of dendritic cells (dc) from dendritic cell progenitors, such as monocytes obtained from peripheral blood. The invention makes it possible to obtain sufficient quantities of a subject's own dc for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease..
Northeastern University

Btla fusion protein agonists and uses thereof

The present invention is based on the seminal discovery that btla agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind btla enhancing btla signaling the present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a btla agonist fusion protein as described herein..
Pfizer Inc.

Novel peptides and analogs for use in the treatment of oral mucositis

Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for innate defense regulator (idr) peptides. Preclinical efficacy results obtained with idrs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure.
Soligenix, Inc.

Radiation therapy with immune response monitoring

A method of treating cancer includes administering a first dose of radiation to a subject; determining a level of a biomarker obtained from the subject, the level indicating an immune response of the subject to the first dose; and not administering a second dose of radiation to the subject unless and until the level of the biomarker is beyond a threshold value.. .
Klinikum Mannheim Gmbh

Immunoadsorption

Upon administration of raav vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with raav vectors, i.e.
Uniqure Ip B.v.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Immunity induction promoting composition, and vaccine pharmaceutical composition

The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing cellular immune response, and a vaccine pharmaceutical composition containing the immunity induction-promoting composition. The present invention relates to an immunity induction-promoting composition containing an immunity induction promoter whose active ingredient is an antimicrobial drug..
Nitto Denko Corporation

Vaccine composition containing synthetic adjuvant

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
Infectious Disease Research Institute

Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use

The present invention is directed toward methods of increasing the immune response to an antigen using tlr1/2 agonist and/or tlr7 agonist in combination with a t cell activating treatment, for example, a vaccine. In some aspects, the present invention provides methods of enhancing an anti-tumor response comprising administering at least one tlr1/2 agonist and/or at least one tlr7 agonist in combination with an immunotherapeutic agent..
Wisconsin Alumni Research Foundation

Vaccine adjuvant composition comprising inulin particles

The present invention provides a pharmaceutically acceptable composition comprising: particles of inulin; a substance comprising or consisting of one or more pathogen-associated molecular patterns (pamps), and an antigen for use inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.. .
Vaxine Pty Ltd

Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs

The presently disclosed subject matter relates to methods and compositions relating to immunostimulatory rna motifs that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.. .
The Trustees Of The University Of Pennsylvania

Methods for enhancing antigen-specific immune responses

Described herein are methods comprising administering to a mammalian subject an effective amount of an annexin chimeric fusion protein, wherein the annexin chimeric fusion protein comprises at least one immunogenic antigen, thereby enhancing the antigen specific immune response relative to administration of the immunogenic antige alone. Methods and kits for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer, are described.
The Johns Hopkins University

Hepatitis c virus immunogenic compositions and methods of use thereof

The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis c virus (hcv) e2 polypeptide and an hcv e1 polypeptide; 2) a variant hcv e1 polypeptide and an hcv e2 polypeptide; or 3) a variant hcv e1 polypeptide and a variant hcv e2 polypeptide, where the variant hcv e2 polypeptide and/or the hcv e1 polypeptide comprises one or more t cell epitopes, present in an hcv polypeptide other than an hcv e1 polypeptide or an hcv e2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes e1 and variant e2, e2 and variant e1, or variant e2 and variant e1.
The Governors Of The University Of Alberta

Materials and methods for respiratory disease control in canines

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of

Hybrid flagellin as a t cell independent vaccine scaffold

A method of immunizing a subject. The method includes administering to the subject an immunogenic amount of a filament including one or more hybrid flagellin proteins, each hybrid protein including a heterologous polypeptide antigen and a portion of a flic flagellin protein.
The Regents Of The University Of California

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector..
The Texas A&m University System

Augmenting the immune response by promoting cell death of immune cells

Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject..
The University Of Vermont And State Agricultural College

Euglena derived composition having immune response inducing components

A composition includes a euglena biomass lysate having an average particle size of about 2.0 to 500 micrometers and cellular components, including beta-1,3-glucan as at least about 90 percent linear, unbranched beta-1,3-glucan polysaccharide polymers having an average molecular weight of 1.2 to 580 kilodaltons (kda) and beta-glucan polymer chains having a polymer length of about 7.0 to 3,400 glucose monomers. Residual media remains from a heterotrophic fermentation process that produced a euglena biomass and the euglena lysate.
Algaeon, Inc.

Needleless syringe and introducing dna into injection target area using same

A needleless injector which can selectively induce the immune response and a method for introducing dna including a region coding for an antigen to selectively produce an antibody in a living body of a mammal by using the needleless injector are provided. Disclosed is a needleless injector for injecting a dna solution into an injection target area without using any injection needle.
Daicel Corporation

Transgenic mouse expressing inactivated human iduronate-2-sulphatase and improving a hunter syndrome treating agent using same

A transgenic mouse expressing inactivated human iduronate-2-sulphatase (ids) and a method for improving agents for treating hunter syndrome using the transgenic mouse are provided. The transgenic mouse expressing the inactivated human ids, which has immune tolerance to ids, does not cause an immune response to ids which is an active component of the agents for treating hunter syndrome, and thus the transgenic mouse may be effectively used to identify immunogenic factors other than the immunogenicity of the protein components of the agents..
Mogam Institute For Biomedical Research

. .

Methods of optimizing nucleotide sequences encoding engineered influenza proteins

The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers.
Sanofi Pasteur, Inc.

Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines

The present disclosure provides methods, vaccines and kits for potentiating an immune response to an antigen in a subject. The methods comprise administering to the subject at least one dose of a depot-forming vaccine comprising one or more antigens in a hydrophobic carrier; and subsequently administering to the subject at least one dose of a non-depot-forming vaccine comprising the one or more antigens..
Immunovaccine Technologies Inc.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(orn)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors

The microbial mimetics exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The mm constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo..

Novel protein structure used for efficient antibody production in immunization

A method of enhancing immune response is provided, including covalent linking an amphipathic peptide to an antigen to form an antigen-complex composition; and administering the antigen-complex to a subject. In addition, a novel antigen-complex with amphipathic helical structure is provided as well, in which the ability of antigen delivery could be improved..
Vaxsia Biomedical Inc.

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Methods for modulating an inflammatory response

The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases il-27r/wsx-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases il-27r/wsx-1 activity..
The Trustees Of The University Of Pennsylvania

Compositions for cellular immunotherapy

The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (car)-modified cd4+ t cells and a composition of cd8+ t cells modified with a distinct car in that the intracellular signaling component of the each car is different, wherein the modified cd4+ and cd8+ t cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer..
Fred Hutchinson Cancer Research Center

Composition and methods for regulating inhibitory interactions in genetically engineered cells

Provided are engineered cells for adoptive therapy, including t cells. Also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects.
Juno Therapeutics, Inc.

Methods of enhancing immune response

The present invention relates to a method of enhancing immune response in a subject.. .
Novartis Ag

Compositions and methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.
President And Fellows Of Harvard College

Modulation of immune response using btla agonist antibodies

The present invention relates to the seminal discovery that btla agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind btla in the activated state enhancing btla signaling.
Sanford-burnham Medical Research Institute

Heterotypic antibodies specific for human rotavirus

Compositions and methods are provided relating to rotavirus serotypes and antibodies that bind to human rotavirus and modifications thereto which enhance the immunogenicity of the rotavirus protein for vaccine development with respect to the generation of a neutralizing immune response. Further disclosed are methods of using the antibodies for treating a rotavirus-mediated disease in a subject..
The Board Of Trustees Of The Leland Stanford Junior University

Histone anti-cancer vaccines

The present invention pertains to novel immunogenic peptide sequences that can be used as vaccines in the treatment of cancer diseases such as brain cancers and specifically glioma. The cancer vaccines of the invention are designed based on the k27m mutated variant of the human histone 3.
Deutsches Krebsforschungszentrum

Normal tissue toxicity reducing microbeam-broadbeam radiotherapy, skin's radio-response immunotherapy and mutated molecular apheresis combined cancer treatments

Normal tissue complications limit curative broadbeam radiotherapy to tumors including lung cancer. Radiation retinitis causing blindness limits quality of life and long term survival for patients with ocular melanoma.

Methods and devices for treatment of tumors with nano-pulse stimulation

Disclosed herein are methods and devices for stimulating an immune response to a disease in a subject, which involves passing sub-microsecond long pulses of electric fields having an amplitude between 5 kv/cm and 68 kv/cm through an abnormal growth of a subject sufficient to suppress myeloid-derived suppressor cell (mdsc) or regulatory t cell (treg) production, increase adenosine triphosphate (atp) or high mobility group box 1 (hmgb1) production, or stimulate dendritic cell activation in the subject.. .
Old Dominion University Research Foundation

Reduction of implant infection via tunable stimulation of localized adaptive immune response

Compositions, implantation devices and methods for stimulating an immune response to infection are discussed. In some examples, the compositions, implantation devices or methods of regulating the amplification of an adaptive immune response to infection involves use of one or more particles locally at a surgical or implant site to control bacterial infections without detrimental systemic side-effects.
Biospheres, Inc.

Interactions between ceacam and tim family members

Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between ceacam family members and tim family members.. .
The Brigham And Women's Hospital, Inc.

Adjuvant particles comprising adenosine receptor antagonists

This document relates to polymeric particles for enhancing the immune response, compositions comprising the polymeric particles, and methods of use thereof. The polymeric particles include a permeation enhancer, an adenosine receptor antagonist, and optionally a biodegradable polymer, wherein the polymeric particles are useful as adjuvant compositions..
Therinject Llc

Compositions, methods and kits for eliciting an immune response

The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one cmv antigen expressed by a cancer cell, in particular for treating and preventing cancer. Cmv determination methods, compositions, and kits also are provided..
Duke University

Malaria antigens and methods of use

The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a plasmodium parasite in a mammal..
Genvec, Inc.

Shared neoantigens

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an hla protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to hla proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.. .
The General Hospital Corporation

Combination therapies with recombinant listeria strains

The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor t cells (car t cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (tki), or an adoptively transferred cells incorporating engineered t cell receptors, and a live attenuated recombinant listeria strain comprising a fusion protein of a truncated llo, a truncated acta or a pest-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment..
Advaxis, Inc.

Inoculation by applying nanosecond pulsed electric fields to a biopsy and reintroducing the treated biopsy to the subject

A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nspef). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells.
Pulse Biosciences, Inc.

Tgf-beta 3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (tgf-β3) are provided, particularly recognizing human and mouse tgf-β3, particularly antibodies and fragments that do not recognize or bind tgf-β1 or tgf-β2. Particular antibodies are provided which specifically recognize and neutralize tgf-β3.
Ludwig Institute For Cancer Research Ltd.

Peptide sequences and compositions

The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a t cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.. .
Peptcell Limited

Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

The present invention relates to infectious dna clones, infectious chimeric dna clones of porcine circovirus (pcv), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (pmws) caused by pcv2. The new chimeric infectious dna clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic pcv1 in which the immunogenic orf gene of the pathogenic pcv2 replaces a gene of the nonpathogenic pcv1, preferably in the same position.
Iowa State University Research Foundation, Inc.

Vaccine candidates against johne's disease

A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, lpqp, map0834c, cspb, lipn, or map1634 of m.
Wisconsin Alumni Research Foundation

Lutzomyia longipalpis polypeptides and methods of use

Substantially purified salivary lu. Longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed.
Fundaçao Oswaldo Cruz (fiocruz)

Cystatin c and cystatin 9 to treat inflammation caused by bacteria

The present invention includes a composition and method for controlling an immune response in a host to a pathogenic bacterial infection comprising: identifying a subject in need of treatment for infection with a pathogenic bacteria; and providing a composition comprising recombinant cystatin 9 (cst9), a cystatin c (cstc), or both cst9 and cstc, in an amount sufficient to restrain or prevent a life-threatening, unrestrained systemic inflammatory response syndrome in a host against a pathogenic bacteria.. .
Board Of Regents, The University Of Texas System

Method of suppressing inflammation and promoting repair of injured neural tissues with carboxyl-functionalized polyurethane nanoparticles

The present invention provides a method of suppressing inflammation and promoting repair of an injured neural tissue in a subject in need thereof, including administering to the injured neural tissue an effective amount of a carboxyl-functionalized polyurethane nanoparticle. The method of the present invention significantly suppresses immune responses by inhibiting pro-inflammatory cytokine production and facilitates neurological recovery, and thus it may be applied directly in patients going through neurosurgery..
National Taiwan University

Simultaneous analysis multiple targets using multiple metal nano-tags

The present invention relates to a simultaneous analysis method for a target using a plurality of metal nano-tags and, more particularly, to a simultaneous analysis method for a target using a plurality of metal nano-tags, wherein the method fuses a nano-particle technology on the basis of an antigen-antibody reaction, which is a conventional biological immune response, and simultaneously diagnoses a plurality of target materials by using a plurality of antigen-antibody reactions and a plurality of metal nano-tags, thereby enhancing diagnostic effect.. .
Specialty Lab Solution Bio Co., Ltd.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cells lacking b2m surface expression and methods for allogeneic administration of such cells

Disclosed herein are cells and populations of cells comprising a genome in which the b2m gene has been edited to eliminate surface expression of mhc class i protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.. .
President And Fellows Of Harvard College

Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein

Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.. .
The Johns Hopkins University

Immunogenic composition comprising engineered alpha-hemolysin oligopeptides

The present disclosure provides immunogenic compositions useful in prevention and treatment of staphylococcus aureus infection. In particular, the present disclosure provides methods of inducing an immune response against an alpha-hemolysin-expressing s.
Integrated Biotherapeutics, Inc.

Interferon-ß production modulating listeria strains and methods for using same

Mutant listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a tetr gene, a ladr gene, a virr gene, a marr gene a mdrl gene, a mdrt gene and a mdrm gene.
The Regents Of The University Of California

Enzymatic immunomodulation of solid tumors and uses thereof

In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting cd26 expression in a subject in need thereof.
University Of Houston System

Combination of tolerogenic peptides and tfg-b for use in the induction and maintenance of oral tolerance in young mammals

This invention relates to the administration of a combination of tgf-β and one or more peptides comprising specific sequences of β-lacto-globulin. The peptides are hypoallergenic but retain the capability to induce tolerance to the native protein.
Nestec S.a.

Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same

The present invention is based, in part, on flagellin adjuvant used to enhance immune responses directed against streptococcus pneumoniae, in particular, to enhance immune responses to polypeptide antigens (e.g., pspa) and capsular polysaccharide from s. Pneumoniae.
Wake Forest University Health Sciences

Humanized t cell mediated immune responses in non-human animals

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized t cell co-receptor (e.g., humanized cd4 and/or cd8 (e.g., cd8α and/or cd8β)), a human or humanized t cell receptor (tcr) comprising a variable domain encoded by at least one human tcr variable region gene segment and/or a human or humanized major histocompatibility complex that binds the humanized t cell co-receptor (e.g., human or humanized mhc ii (e.g., mhc ii α and/or mhc ii β chains) and/or mhc i (e.g., mhc i α) respectively, and optionally human or humanized β 2 microglobulin). Also provided are embryos, tissues, and cells expressing the same.
Regeneron Pharmaceuticals, Inc.

Pathway specific assays for predicting irritable bowel syndrome diagnosis

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays the present invention also provides stable derivatives of various metabolites and short chain fatty acids.
Nestec S.a.

Method of stimulating tlr9-activated immune response

A method of stimulating a tlr9-activated immune response or enhancing a tlr9-activated immune response to an antigen is disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
National Health Research Institutes

Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same

Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte

Novel immunomodulatory therapeutic strategies targeting tumors in cancer

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting abcb5 and an immune checkpoint molecule related pathways using various therapeutic agents such as antibody or small molecule. The present invention also provides use of an abcb5 inhibitor and an immune checkpoint inhibitor(s) for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors..
Bioxcel Corporation

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Influenza nucleic acid molecules and vaccines therefrom

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotpyes using the vaccines that are provided..
The Trustees Of The University Of Pennsylvania

Compositions, methods and therapies for administering antigen peptide

The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with propionibacterium acnes. The compositions include a combination of peptide and anti-tnf.

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy, immunotherapy, and vaccination optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy.

Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

The disclosure features, inter alia, immunogenic xbp1-, cd138-, and cs1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or waldenstrom's macroglobulinemia).
Dana-farber Cancer Institute, Inc.

Method for treating cancer

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (mhc), or cancer, characterized by aberrant, misregulated, or increased enhancer of zeste homolog 2 (ezh2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an ezh2 inhibitor.. .
Epizyme, Inc.

Beta-glucan assay methods

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to β-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody compared to a reference standard, computing a relative antibody unit (rau) value for anti-β-glucan antibody in the sample, and identifying the subject as biomarker positive if the rau value is greater than a predetermined rau value for the biomarker anti-β-glucan antibody..
Biothera, Inc.

Dendritic cell immunotherapy

Methods of providing a targeted immune response in a subject comprising administration of a dendritic cell population are provided. In some aspects, dendritic cells are administered in conjunction with a type i interferon (inf), a tlr-7 agonist, a tlr-9 agonist, aimp1, a tlr-3 agonist, a retinoic acid inducible gene-1 (rig-1)-like receptor ligand or a cytosolic dna (cds) receptor ligand and/or are administered to a tissue site proximal to diseased tissue.
Baylor College Of Medicine

Antibodies that modulate immunity to drug resistant and latent mtb infections

The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (mdr) mtb and extremely drug resistant (xdr) mtb. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to mtb and/or antibodies that are specifically reactive to mtb antigens.
Longhorn Vaccines And Diagnostics, Llc

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Wherein r1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein r1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and r2 is —n+(ch3)3..

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l; (lys)m; (his)n; (orn)o; (xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Antibody-vaccine engineered constructs (avec)

Hereby, we disclose and claim, the concept, designs, enabling technologies, and utility for therapy of patients suffering from cancer, of a novel class of biomolecularly engineered, synthetic molecules: antibody-vaccine engineered constructs (avec). They comprise the main functional domains (antibodies and vaccines) and the supporting domains (linkers and reporters).
Phoenix Biomolecular Engineering Foundation

Modulation of the immune response

Methods for identifying compounds that modulate the generation of regulatory t cells (treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of foxp3.. .
The Brigham And Women`s Hospital, Inc.

Poxviral vaccines

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed..
Glaxosmithkline Biologicals, Sa

Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

This disclosure relates to recombinant bacteria, e.g. L.
Emory University

Immunogenic compositions and uses thereof

The invention relates to immunogenic compositions comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against gbs and/or for reducing or preventing invasive gbs disease in subjects using the compositions disclosed herein.
Pfizer Inc.

Placental vaccination therapy for cancer

The present invention discloses methods of stimulating an immune response to cancer tissue and biological effectors used by tumors to defeat the host, through the immunization of a mammal using placental tissue, cells, molecules, and combinations thereof. In one embodiment, the invention provides the utilization of syngeneic, allogeneic, xenogeneic, and combinations thereof as immunizing sources..

Virus-like particle with efficient epitope display

The invention relates to a virus-like particle (vlp) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject.
University Of Copenhagen

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen.
Curevac Ag

Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds

The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of irreversible electroporation (ire) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact.
Virginia Tech Intellectual Properties, Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Longwood Gardens, Inc.

Cxcl13 as an indicator of germinal activity and immune response

Presented herein are methods of detecting and/or monitoring germinal center activity in a subject according to an amount of cxcl13 in the blood of a subject. Also presented herein are methods of determine the efficacy of a vaccine or antigen at inducing an immune response.
La Jolla Institute For Allergy And Immunology

Compositions and methods for diminishing an immune response

The invention is based upon the discovery that t regulatory type 1 (tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer tr1 cells allows for improved methods of tr1 therapies for treating a wide variety of diseases and disorders..
Fondazione Telethon

Anti-muc16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind muc16 and cd3, and uses thereof

Mucin 16 (muc16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human igg antibodies that bind to human and muc16 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Variant survivin vaccine for treatment of cancer

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (apcs) such as dendritic cells, or apc precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or apc.. .
The Wistar Institute

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Dna-based plasmid formulations and vaccines and prophylactics containing the same

The invention is a general method for improving the performance of the dna-based vaccines. The method utilizes a complex dna-generated profile of antigens to extend the effects of dna-based vaccines and to broaden the immune response.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Immunoconjugates for programming or reprogramming of cells

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.. .
President And Fellows Of Harvard College

Targeted cytosolic delivery of antigenic compounds

The invention relates to engineered anthrax toxin compositions that can target antigen-presenting cells such as dendritic cells. Specifically, the compositions comprise (a) a native-receptor-ablated anthrax toxin protective antigen (pa) fused to a receptor-binding moiety specific for a target receptor on a dendritic cell and (b) a lethal factor (lf) or a fragment thereof fused to an active moiety comprising at least one repeat of a disease-specific antigen.
President And Fellows Of Harvard College

Immune complex

The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (ic) or immune complexes (ics), which take advantages of type ii fc receptor (fcr) interactions and signaling to elicit broader and more potent protective immune responses.
The Rockefeller University

Mosaic vaccines for serotype a foot-and-mouth disease virus

Synthetic foot-and-mouth disease virus (fmdv) mosaic polypeptides, and nucleic acid molecules encoding the mosaic polypeptides, are described. The mosaic polypeptides have greater t-cell epitope coverage than naturally occurring fmdv polypeptides, and include common fmdv epitopes, but exclude rare fmdv epitopes.
Los Alamos National Security, Llc

Conformationally specific viral immunogens

The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine..

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods for enhancing an immune response with a ctla-4 antagonist

Methods are provided for enhancing an immune response comprising providing an immunogenic composition in conjunction with a ctla-4 antagonist. Dendritic cell populations having reduced ctla-4 expression are likewise provided..
Baylor College Of Medicine

Antibodies against human nkg2d and uses thereof

The present invention provides isolated anti-human nkg2d monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient.
Novo Nordisk A/s

Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

The protein known as six-transmembrane epithelial antigen of prostate 2 (steap2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human igg antibodies that bind to human steap2 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Methods and compositions for activation of innate immune responses through rig-i like receptor signaling

Compositions and methods are provided that enable activation of innate immune responses through rig-i like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (pamps) that comprise elements initially characterized in, and derived from, the hepatitis c virus genome..
University Of Washington Through Its Center For Commercialization

Immunogenic composition

Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from streptococcus agalactiae (gbs) serotypes conjugated to carrier proteins.. .
Glaxosmithkliine Biologicals Sa

Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof

The present invention relates to compositions comprising a recombinant attenuated listeria strain expressing a truncated acta and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant listeria strain that expresses a fusion protein of a truncated acta fused to an antigen..
Advaxis, Inc.

System and imaging macrophage activity using delta relaxation enhanced magnetic resonance imaging

A magnetic resonance imaging (mri) system is provided for imaging immune response of soft tissue to therapy by, prior to therapy, administering a contrast agent to the soft tissue; imaging a region of interest using delta relaxation enhanced magnetic resonance (dremr) to define a functional section; selectively sampling local cells in the functional section; conducting immuno-assay analysis on the sampled local cells; and following therapy, further imaging said region of interest using dremr to assess immune response of said cells to therapy.. .

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer..
Engenelc Molecular Delivery Pty. Ltd.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Lymph node-targeting nanoparticles

Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. A cytokine.
Duke University

Methods to improve induction of iga antibodies by vaccines

A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an iga response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil inhibitor in an amount effective to promote an iga response to the vaccine antigen in the subject..
Ohio State Innovation Foundation

Anti-fugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides antifugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Vaccine compositions and methods of use thereof

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e.g. Tumor cells).
University Of Miami

Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding protein

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting lgals3bp-cd33 related siglec pathway using antibody or antibody-drug conjugate therapy. The present invention also provide use of anti-lgals3bp antibody in combination with an immune checkpoint inhibitor for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors and metastases thereof.
Bioxcel Corporation

Mosaic chimeric viral vaccine{[s]] particle

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response.
The Texas A&m University System

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and reagents to treat autoimmune diseases and allergy

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen.

Methods and compositions for affecting immunological responsiveness

A method of treating a subject having a deficient immune response is described. The method includes administering a therapeutically effective amount of non-immune drug, or an analog or metabolite thereof, known to induce one or more autoimmune syndromes to the subject.
Cellprint Ip Holding, Llc

Modulators of myc, and methods of using the same

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response.
Taiga Biotechnologies, Inc.

Virotherapy with an antibody combination

Disclosed herein are viruses that can be used in methods of treatment for cancer. More specifically, the viruses express two or more antibodies which induce an effective anti-tumor immune response.
Stemimmune, Incorporated

Small molecule enhancer for dendritic cell cancer vaccines

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
Trustees Of Tufts College

Thermostable vaccine compositions and methods of preparing same

Compositions relating to thermostable vaccines and methods of preparing same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject..
Soligenix, Inc.

Oregon Health & Science University

. .

Methods and products for evaluating an immune response to a therapeutic protein

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e.g., natalizumab)..
Biogen Ma Inc.

Cytomegalovirus vectors enabling control of t cell targeting

Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul128 protein (or an ortholog thereof) but lacking an active ul130 protein (or an ortholog thereof) are provided. Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul130 protein (or an ortholog thereof) but lacking an active ul128 protein are also provided.

Method for reducing the immune response to a biologically active protein

A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal..
Affibody Ab

Mutated salmonella enterica

A novel, mutated salmonella enterica serovar typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of s. Enterica serovars.
The United States Of America, As Represented By The Secretary Of Agriculture

Vaccines with cd40 ligand as an adjuvant

Disclosed herein is a vaccine comprising an antigen and cd40l. Also disclosed herein are methods for increasing an immune response in a subject.
Inovio Pharmaceuticals, Inc

Immunogenic fusion proteins for the treatment of cancer

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins..
The Johns Hopkins University

Vaccination with anti-tick antigens to control multiple tick species and disease transmission in white-tailed deer and other host animals

Compositions of either the rm86texas protein from a texas outbreak strain of the southern cattle fever tick, rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this rm86texas protein, are effective for eliciting a protective immune response in non-bovine animals. The rm86texas protein is immunogenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a dna vaccine.
Louisiana State University

Sting (stimulator of interferon genes), a regulator of innate immune responses

Novel molecules termed sting which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. Sting compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity..
University Of Miami

Additives for animal feed

The present invention relates to the combination of organic acid salts with at least one active ingredient of plant origin, preferably essential oils, partially protected with vegetable fats and/or oils, which prevent these active ingredients from being digested by stomach enzymes during the digestive process. The sodium salts of short-chain acids, preferably salts of butyric, acid are preferred.
Norel, S.a.

Delivery of rna to trigger multiple immune pathways

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Glaxosmithkline Biologicals, Sa

Methods of determining an immune response score

The present disclosure provides method for determining an immune response score (irscore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irscore=x(low, medium, or high), wherein x is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.. .
American Molecular Laboratories Inc.

Anti-h7cr antibodies

Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University

Cdca1-derived peptide and vaccine containing same

The present invention provides cdca1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Isg15 and its use as an adjuvant

Disclosed herein is a vaccine comprising an antigen and isg15. Also disclosed herein is a method for increasing an immune response in a subject in need thereof.
The Trustees Of The University Of Pennsylvania

Epitopes from allergen proteins and methods and uses for immune response modulation

The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject..
La Jolla Institute For Allergy And Immunology

Vhh constructs for diverting an immune response

The invention relates to a novel vhh construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the vhh construct being impaired. The invention also relates to an antibody construct comprising a vhh construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics.
Preclinics Gesellschaft Fuer Praeklinische Forschung Mbh

Synthetic immunogens for prophylaxis or treatment of tuberculosis

Compositions comprising a nucleic acid molecule that encodes tb esat-6 proteins are disclosed. Methods of inducing an immune response against tb an individual are disclosed.
The Trustees Of The University Of Pennsylvania

Combination of vaccination and inhibition of mhc class i restricted antigen presentation

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (mhc) class i restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination.
Curevac Ag

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami

Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors

The present disclosure relates to modified vaccinia ankara (mva) virus or mvaae3l delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor..
Memorial Sloan Kettering Cancer Center

Vaccines based on hepatitis b core antigens

The invention provides a protein comprising hepatitis b core antigen (hbcag) with a sequence of the formula xpzqxr in an e1 loop, wherein x is a negatively charged amino acid residue, z is a positively charged amino acid residue, and p, q n and r are each independently an integer from 1 to 12, and wherein a sugar is attached to a z residue. The protein may comprise a first and a second copy of hbcag in tandem, wherein one or both copies of hbcag has a sugar attached to the e1 loop.
Iqur Limited

Compositions and methods for detecting, treating, and protecting against fusobacterium infection

The present invention relates to protecting against, treating, and detecting fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kda adhesin protein are provided to protect against, treat, and detect fusobacteria infections in a subject.
Kansas State University Research Foundation

Transcutaneous haemophilius influenzae vaccine formulations and methods

Provided are topical delivery systems and methods for treating and/or preventing a disease or disorder in a subject, or for eliciting an immune response in a subject including applying, to at least a portion of the subject's post-auricular region, a topical delivery system including a therapeutically effective amount of a topical pharmaceutical composition comprising at least one active agent and a pharmaceutically acceptable carrier and/or adjuvant. The topical pharmaceutical composition can include a topical immunogenic composition.
Research Institute At Nationwide Children's Hospital

Subunit vaccine delivery platform for robust humoral and cellular immune responses

The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed..
Cornell University

Use of agents that alter the peritumoral environment for the treatment of cancer

The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide nk1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor.
Servicio Andaluz De Salud

Recombinant aav vectors useful for reducing immunity against transgene products

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.. .
Suntory Flowers Limited

Live attenuated vaccines for pneumoviruses and related methods and materials

Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an m2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic.
Ohio State Innovation Foundation

Modified foot-and-mouth disease virus 3c proteases, compositions and methods thereof

This application is directed generally to foot-and-mouth disease virus (fmdv) 3c proteases that have been modified by mutating a polynucleotide sequence coding for the fmdv 3c protease. The modified fmdv proteases exhibit proteolytic activity on fmdv p1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified fmdv 3c protease on a host cell used to recombinantly produce it.
The Government Of The United States Of America, As Represented By The Secretary Of Homeland Security

Detection of t cell exhaustion or lack of t cell costimulation and uses thereof

The application relates to methods of assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and the use of such methods in determining an individual's risk of autoimmune disease progression, progression of a chronic infection, not responding to a treatment for a chronic infection, not mounting an effective immune response to vaccination, infection-associated immunopathology, transplant rejection, or cancer progression. The application also relates to in vitro methods for assessing whether cd8+ and cd4+ t cells in a sample have an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and for identifying a substance capable of inducing an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype in an individual, as well as a kit for assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype or whether an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype is present in a sample of cd8+ and cd4+ t cells..
Cambridge Enterprise Limited

Anti-h7cr antibodies

Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University

Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to lag-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human lag-3.
E. R. Squibb & Sons, L.l.c.

Compositions and methods for regulating sas1r

The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, sas1r (sperm acrosomal sllp1 receptor), which is a sperm protein receptor. Six sas1r variants, including the full length sas1r, were identified.
University Of Virginia Patent Foundation

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Class i mhc phosphopeptides for cancer immunotherapy and diagnosis

A set of phosphorylated peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive t-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease.
Agenus Inc.

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Methods for inducing an immune response against human immunodeficiency virus (hiv) in hiv-infected subjects undergoing antiretroviral therapy (art) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (mva) vector booster vaccine encoding mosaic hiv antigens..
Walter Reed Army Institute Of Research

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as an active ingredient

The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.. .

Listeria-based immunogenic compositions for eliciting anti-tumor responses

The present invention is directed to compositions comprising an immune checkpoint inhibitor or a t cell stimulator or a combination thereof, and a live attenuated recombinant listeria strain comprising a fusion polypeptide comprising a truncated listeriolysin o protein, a truncated acta protein, or a pest amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Compositions and methods for suppressing or reducing systemic immune response in a subject

The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof..
The Trustees Of The University Of Pennsylvania

Systems and methods for targeted uvb phototherapy for dermatologic disorders and other indications

The present disclosure is directed to systems and methods for targeted uvb phototherapy for dermatologic disorders and other indications. In one embodiment, a phototherapeutic system can include a radiation source configured to emit light.
Benesol, Inc.

Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages.
Oregon Health And Science University

Method

The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination.
Pci Biotech As

Delivery of rna to different cell types

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Glaxosmithkline Biologicals, Sa

Car-expressing cells against multiple tumor antigens and uses thereof

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., t cells, nk cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a chimeric antigen receptor (car). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a car, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine..
The Trustees Of The University Of Pennsylvania

Influenza virus vectors and uses therefor

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.

Multimodal antimicrobial therapy

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment.
Longhorn Vaccines And Diagnostics, Llc

Urlc10-derived peptide and vaccine containing same

The present invention provides urlc10-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Immuno-regulatory lipid containing spherical nucleic acids

Immunoregulatory spherical nucleic acids (irsnas) composed of a lipid containing core and an inert nucleic non-tlr antagonistic oligonucleotide shell are provided. Acid shell these it-snas are useful for modulating an immune response..
Exicure, Inc.

Beta-catenin inhibitors in cancer immunotherapy

Provided herein are compositions and methods for the treatment of cancer by inhibition of β-catenin or a β-catenin pathway. In particular, inhibitors of β-catenin and/or the wnt/p-catenin signaling pathway are employed prevent or reverse evasion of immune response or immuno-therapy by cancers..
The University Of Chicago

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compositions and methods for enhancing an immune response

The disclosure features compounds comprising an antigen portion, a soluble major histocompatibility complex (mhc) molecule portion (e.g., all or an antigen-binding portion of a soluble mhc class i molecule), and a dynamic anchor portion (e.g., an agent, such as annexin v, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e.g., enhancing a t cell response to an antigen of interest or enhancing a t cell-driven immune response by a subject to an antigen of interest (e.g., a cancer antigen or a microbial antigen)..
The Johns Hopkins University

Molecular antigen array

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Kuros Biosciences Ag

Anti-tumor vaccine derived from normal cells

A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation.
Cytovac A/s

Rna containing compositions and methods of their use

The present invention relates to a composition comprising an isolated, single stranded rna molecule having a nucleotide sequence comprising 20 or more bases and a pattern of cpg dinucleotides defined by a strength of statistical bias greater than or equal to zero, and a pharmaceutically acceptable carrier suitable for injection. The present invention also relates to a kit comprising a cancer vaccine and the composition of the present invention as an adjuvant to the cancer vaccine.
Ecole Normale Superieure

Method for treating hiv

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones.
Enzo Therapeutics, Inc.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.
Hogenboom Phloxen

Modified antibody

Recombinant antibody-based molecules that trigger both t-cell and b-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif.
Vaccibody As

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Synthetic glucopyranosyl lipid adjuvants

Or a pharmaceutically acceptable salt thereof, wherein l1. L2, l3, l4, l5, l6, l7, l8, l9, l10, y1,y2, y3, y4, r1, r2, r3 , r4, r5, r6, are as defined herein.

Polyelectrolyte multilayers assembled from immune signal compounds

Immune-polyelectrolyte multilayers (ipems) that can be made entirely from immune signal compounds are provided. Ipems are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound.
University Of Maryland, College Park

Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections

Nucleic acid molecules which encode an mrsa pbp2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed.
The Trustees Of The University Of Pennsylvania

Immunogenic/therapeutic glycan compositions and uses thereof

The present disclosure encompasses immunogenic/therapeutic compositions including globo series antigens (ssea-4, globo h or ssea-3) glycoconjugates and therapeutic adjuvants (obi-821 or obi-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier.
Obi Pharma, Inc.

Immunotherapeutic vaccine and antibody combination therapy

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s)..
Transgene Sa

Administration of plant expressed oral tolerance agents

Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is other complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of ige. Using murine hemophilia b as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells.
The Trustees Of The University Of Pennsylvania

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Bispecific binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein.
Medimmune, Llc

Antibodies to l-type voltage gated channels and related methods

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of l-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.. .
Biommune Technologies Inc.

Cytomegalovirus-based vaccine expressing ebola virus glycoprotein

A recombinant herpesvirus-based vector comprising a nucleic acid sequence encoding a heterologous antigen and a promoter for controlling the expression of the antigen, in which the promoter is expressed at a time selected to provide a required immune response in a subject.. .
The Regents Of The University Of California

Methods and compositions for attenuated chlamydia as vaccine and vector

The present invention provides chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.. .
Board Of Regents, The University Of Texas System

Methods and compositions for inducing an immune response to egfrviii

The present invention relates to methods of inducing a t-cell response against a egfrviii in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of egfrviii polypeptide sequences, the sequence of which each comprise eekkgnyv (seq id no: 3), and/or administering the polypeptide itself..
Providence Health & Services - Oregon D/b/a Providence Portland Medical Center

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Tnfrsf-binding agents and uses thereof

Polypeptides and agents that bind a tnf receptor superfamily protein are disclosed, particularly agents that specifically bind gitr, ox40, or cd40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising gitrl, ox40l, or cd40l and/or bispecific agents.
Oncomed Pharmaceuticals, Inc.

Methods of modulating immune and inflammatory responses via administration of an algal biomass

An algal biomass and supernatant derived from at least one species of algae exhibits anti-inflammatory and immune response modulating properties. Methods of reducing the symptoms of or treating a condition or disease in an animal, including bovine mastitis and bovine respiratory disease complex, and the pain and discomfort caused by osteoarthritis, injury or overexertion or muscle and connective tissue strains, comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or biologically active compound derived from the algae species, biomass or supernatant, or compositions thereof..
Zivo Bioscience, Inc.

Inhibition of yap for breaking tumor immune tolerance

Yes-associated protein (yap), a downstream co-activator of the hippo pathway, is highly expressed in the treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in drosophila melanogaster, the hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals.
The Johns Hopkins University

Novel multivalent nanoparticle-based vaccines

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus.
The Usa, As Represented By The Secretary Department Of Health And Human Services

Compositions and methods for improved skin care

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen..

Genetic factors associated with inhibitor development in hemophilia a

The present invention provides methods for predicting the risk of an individual developing antibodies to factor viii by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes..

Method for rapid in vitro synthesis of bioconjugate vaccines via recombinant production of n-glycosylated proteins in prokaryotic cell lysates

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines.
Cornell University

Recombinant cytomegalovirus vectors as vaccines for tuberculosis

The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising mycobacterium tuberculosis (mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.. .
Oregon Health And Science University

Fcrn antibodies and methods of use thereof

The present invention features antibodies that have high binding affinity to human neonatal fc receptor (fcrn). These anti-fcrn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject..
Momenta Pharmaceuticals, Inc.

Synthetic nanoparticles for delivery of immunomodulatory compounds

The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (pna) oligomer conjugated to a lipid, wherein the pna oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases..
Massachusetts Institute Of Technology

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject.
Inovio Pharmaceuticals, Inc.

In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus-like particles

The invention relates to the finding that stimulation of antigen presenting cell (apc) activation using substances such as anti-cd40 antibodies or dna oligomers rich in non-methylated c and g (cpgs) can dramatically enhance the specific t cell response obtained after vaccination with recombinant virus like particles (vlps) coupled, fused or otherwise attached to antigens. While vaccination with recombinant vlps fused to a cytotoxic t cell (ctl) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, vlps injected together with anti-cd40 antibodies or cpgs induced strong ctl activity and full anti-viral protection.
Kuros Biosciences Ag

Attenuated pasteurella multocida vaccines & methods of making & use thereof

The present invention provides attenuated p. Multocida strains that elicit an immune response in animal p.
Merial Inc.

Polymer particles and uses thereof

The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof in eliciting a cell-mediated immune response and in the treatment or prevention of diseases or conditions including those caused by intracellular pathogens..
Polybatics Limited

Stimulation of an immune response by enantiomers of cationic lipids

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (i); wherein in r1 is a quaternary ammonium group, y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, c* is a chiral carbon, r2 and r3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof..
Pds Biotechnology Corporation

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Klemm+sohn Gmbh & Co. Kg

Method and compositions for cellular immunotherapy

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a poly nucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain.
Seattle Children's Hospital (dba Seattle Children's Research Institute)

Alternative nucleic acid molecules containing reduced uracil content and uses thereof

The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mrna wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response.
Modernatx, Inc.

Nucleic acids for treatment of allergies

The present invention provides dna vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (lamp) and the targeting sequence of lamp.
Immunomic Therapeutics, Inc

Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells

The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.. .
Imnate Sarl

Lipid a mimics, methods of preparation, and uses thereof

The invention provides lipid a mimics in which one or both of the sugar residues of a natural lipid a disaccharide backbone has been replaced with an aromatic group. These lipid a mimics may further differ from a natural lipid a molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements).
Immunovaccine Technologies Inc.

Alum-containing coating formulations for microneedle vaccine patches

Compositions for coating microneedles with aluminum-adjuvanted vaccines are provided comprising an aluminum-containing wet gel suspension selected from aluminum hydroxide wet gel suspension and aluminum phosphate wet gel suspension; a vaccine in an amount effective to stimulate an immune response in a mammal; a sugar, sugar alcohol, or combinations thereof; and a thickener. Some embodiments of the compositions have a viscosity of 500 to 30,000 cps when measured at 100 s−1 and temperature of 25 c.
3m Innovative Properties Company

Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses..
Celltrion Inc.

Methods and compositions for induction of immune response

The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided..
Zoetis Services Llc

Recombinant metapneumovirus f proteins and their use

Metapneumovirus (mpv) f proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the mpv f proteins and/or nucleic acid molecules can be used to generate an immune response to mpv in a subject.
Institute For Research In Biomedicine

Influenza virus vaccination regimens

Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (ha), a headless ha or another influenza virus stem domain based construct (e.g., the ha stem domain or a fragment thereof) to a subject.
Icahn School Of Medicine At Mount Sinai

Method and compositions for enhancing immunotherapeutic treatment of a cancer

Provided are methods and compositions for enhancing treatment of a cancer by administering a therapeutic agent for the treatment of a cancer together with a second agent that elevates the level of protein p53. The second agent generates in the tumor a population of dendritic cells expressing at least one of batf3, irf5, cd103, and xcr1.
Augusta University Research Institute, Inc.

Autologous tumor vaccines and methods

Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.. .
Vaccinogen, Inc.

Sheep nematode vaccine

The present invention is based upon the identification of a number of antigens derived from species of the genus teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate teladorsagia infections/infestations..
Moredun Research Institute

Methods for enhancing efficacy of therapeutic immune cells

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—car) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule ci for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof..
National University Of Singapore

Human ebola virus species and compositions and methods thereof

Compositions and methods including and related to the ebola bundibugyo virus (ebobun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from ebobun challenge in a subject such as a primate.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents

The present invention relates to methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents.. .
Dana-farber Cancer Institute, Inc.

Amino acid and peptide conjugates and uses thereof

The present invention relates to peptides, and amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the peptides and conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the peptides and conjugates for the same, and uses of the peptides and conjugates in the manufacture of medicaments for the same.. .

Device and administering an anti-cancer substance

An anti-cancer substance is administered via the patient's blood ex vivo and in line by establishing a connection between the patient and a device having a chamber containing the anti-cancer substance. The patient's blood in the chamber and the anti-cancer substance interact so that immune cells in the blood (1) are activated to produce an immune response in the patient, or (2) are pre-armed by attaching to the cells antibodies, or (3) both.

Method and device for treating cancer

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions.

Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)

Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (aat) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an alpha-1 antitrypsin (aat) encoding region operably linked to (ii) a promoter or promoter/enhancer combination..
Apceth Gmbh & Co. Kg

Methods of inducing an immune response to hepatitis c virus

The present disclosure provides methods for inducing an immune response to hepatitis c virus (hcv) in an individual. The present disclosure provides methods for treating an hcv infection in an individual..

Viral rna segments as immunomodulatory agents and vaccine components

The disclosure provides compositions and methods involving viral rna segments for use in modulating immune responses, including inhibition inflammation related to pathogenic t-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations..
The University Of Iowa Research Foundation

Imp-3 epitope peptides for th1 cells and vaccines containing the same

Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to mhc class ii molecules and induce imp-3-specific cytotoxic t lymphocytes (ctls) in addition to th1 cells.
Oncotherapy Science, Inc.

Methods for profiling the t cell repertoire

The present disclosure relates to methods for profiling subject specific and personalized t cell receptor (tcr) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of t cell receptors to subject specific neoantigens.
Dana-farber Cancer Institute, Inc.

Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity

Provided are polynucleotides and viral vectors, particularly, alphavirus vectors such as sindbis viral vectors, which encode multiple, e.g., two or more, epitopes of at least one tumor associated antigen in which each epitope is separated by a processing or enzyme cleavage site. The multiple epitopes of the two or more tumor associated antigens encoded by the described polynucleotides and viral vectors may be the same or different.
New York University

Methods for immunomodulation of cancer and infectious disease therapy

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (trip) compound with an effective amount of the therapeutic agent. In particular embodiments, the trip compound enhances the immune response of the subject to the therapeutic agent.
The Regents Of The University Of California

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided..
Board Of Regents, The University Of Texas System